Gelesis Holdings Inc. Stock Analysis GLSHQ
United States Health Care Nano Cap Gelesis Holdings, Inc. operates as a biotechnology company. The company is headquartered in Boston, Massachusetts and currently employs 93 full-time employees. The company went IPO on 2020-07-07. The firm focuses on advancing superabsorbent hydrogel therapeutics for chronic gastrointestinal (GI) diseases including excess weight, type two diabetes, Nonalcoholic Fatty Liver Disease (NAFLD)/ Nonalcoholic Steatohepatitis (NASH), functional constipation (FC), and inflammatory bowel disease. Its product, Plenity, is an orally administered capsule. Plenity is available by prescription via a telehealth consultation with a physician trained in weight management support, with free, unlimited follow-up visits as needed. Consumers can visit myplenity.com for online consultations. Its other pipeline candidate includes GS200 for weight loss in prediabetes and type two diabetes. The company is also developing GS300 for the treatment of NAFLD and NASH, and GS500 for the treatment of Functional Constipation (FC).
Read More Gelesis Holdings Inc (GLSHQ) Chart
Financial Metrics & Statements of Gelesis Holdings Inc (GLSHQ)
FAQ's for Gelesis Holdings Inc (GLSHQ)
- According to Musaffa’s Shariah screening methodology, Gelesis Holdings Inc (GLSHQ) is currently classified as NOT COVERED as of May 2026. The classification is based on an evaluation of the company’s business activities and financial ratios to determine whether it meets Islamic investment guidelines.